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Unrestricted Use of Drug-Eluting Stents Compared
With Bare-Metal Stents in Routine Clinical Practice
Findings From the National Heart,
Lung, and Blood Institute Dynamic Registry
J. Dawn Abbott, MD, FACC,* Matthew R. Voss, MD,* Mamoo Nakamura, MD,†
Howard A. Cohen, MD, FACC,‡ Faith Selzer, PHD,† Kevin E. Kip, PHD, Helen A. Vlachos, MSC,†
Robert L. Wilensky, MD, FACC,§ David O. Williams, MD, FACC*
Providence, Rhode Island; Pittsburgh and Philadelphia, Pennsylvania; and New York, New York
Objectives We investigated the effectiveness and safety of drug-eluting stents (DES) as used in routine clinical practice.
Background Randomized trials have shown that DES prevent target vessel revascularization in selected patients, but whether
this translates into superior outcomes, compared with bare-metal stents (BMS), for the full spectrum of patients
treated with DES in North America is unknown.
Methods Patients in the National Heart, Lung, and Blood Institute Dynamic Registry enrolled in 2004 who received at
least 1 DES (n  1,460) were compared with 1,763 patients enrolled in the recruitment period immediately pre-
ceding the approval of DES (2001 to 2002) who received at least 1 BMS.
Results Patients receiving DES more often had diabetes mellitus and less often presented with an acute myocardial
infarction (MI). At 1 year, cumulative death and MI was 7.6% in DES- and 8.7% in BMS-treated patients (ad-
justed hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.68 to 1.15; p  0.34). The 1-year rate of tar-
get vessel revascularization was 5.0% in DES and 9.2% in BMS patients (p  0.001), and the risk of any
repeat revascularization by percutaneous coronary intervention or coronary bypass was lower in DES pa-
tients (adjusted HR 0.38, 95% CI 0.25 to 0.60; p  0.001). Patients with both simple and complex lesion
characteristics benefited from DES with lower risk of repeat target vessel revascularization by percutaneous
coronary intervention compared with BMS (any complex lesion: adjusted HR 0.57, 95% CI 0.39 to 0.83; ab-
sence of any complex lesion: adjusted HR 0.44, 95% CI 0.28 to 0.71). The 1-year incidence of stent throm-
bosis was 1.0% in DES patients.
Conclusions The generalized use of DES resulted in better outcomes than BMS, with fewer clinically driven revascularization
procedures and similar rates of death and MI at 1 year. (J Am Coll Cardiol 2007;50:2029–36) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.071w
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although the effectiveness of drug-eluting stents (DES)
n reducing in-stent restenosis and target vessel revascu-
arization has been confirmed in many patient and lesion
ubsets (1–11), questions remain regarding their gener-
lized use. Even in clinically stable patients with de novo
esions enrolled in randomized trials comparing DES
rom the *Department of Cardiology, Rhode Island Hospital, Providence, Rhode
sland; †Graduate School of Public Health, University of Pittsburgh, Pittsburgh,
ennsylvania; ‡Lenox Hill Heart and Vascular Institute, New York, New York; and
he §Cardiovascular Division, Hospital of the University of Pennsylvania, Philadel-
hia, Pennsylvania. The Dynamic Registry is supported by grant HL033292-21
rom the National Heart, Lung, and Blood Institute of the National Institutes of
ealth. See accompanying online Cardiosource Slide Set.p
Manuscript received February 16, 2007; revised manuscript received June 27, 2007,
ccepted July 2, 2007.ith bare-metal stents (BMS), there is concern regarding
ate stent thrombosis rates (12–17). The risk of stent
hrombosis may be exaggerated in unselected populations
reated with DES and may be related to adjunctive
See page 2037
ntiplatelet therapy, but whether this risk is different
rom similar patients treated with BMS is unclear (18 –
0). Importantly, since their commercialization DES
ave been universally accepted as superior to BMS and
re being used for most patient and lesion subsets and in
s many as 95% of stent procedures (21–22). To this
oint, data comparing such use of DES with BMS in
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Therefore, we compared 2 pa-
tient cohorts from the multi-
center National Heart, Lung,
and Blood Institute Dynamic
Registry, one consisting of con-
secutive patients treated with at
least 1 DES and the other of
patients treated with a BMS just
before approval of DES.
Methods
tudy design and patient population. The Dynamic Reg-
stry is a prospective observational study of consecutive
atients undergoing percutaneous coronary intervention
PCI) at selected clinical centers in North America during
respecified time intervals or “waves.” Five enrollment
aves of approximately 2,000 consecutive patients each have
een collected over the past 10 years. Each wave is intended
o capture an experience with specific new device technol-
gies and examine trends in PCI. Enrollment for wave 3
as completed between October 2001 and March 2002 and
epresented the last wave before the routine availability of
ES. Wave 4 extended from February 2004 to May 2004,
time when both BMS and DES were routinely available.
reliminary review of wave 4 findings, however, indicated a
ubstantial bias in stent selection with a predominance of
igher-risk patients, such as those with acute MI, more
ften receiving BMS. Accordingly, for the present BMS
nd DES comparison, BMS patients were selected from
ave 3, in which patient selection was more similar to that
f the DES patients in wave 4. For this analysis, only
atients who received a stent are included. From a total of
,047 patients recruited in wave 3, 1,763 received 1 or more
MS. Wave 4 recruited 2,112 patients of which 1,460
eceived at least 1 DES.
ata collection and protocol. For each wave, demo-
raphic, clinical history, baseline angiographic, and proce-
ural data during the index PCI hospitalization and 1-year
ollow-up events were collected by trained research coordi-
ators who used standardized report forms and were guided
y a manual of operations and definitions. Information
bout in-hospital outcomes was obtained from review of
ospital records and coronary angiograms. All information
as site determined. Follow-up data were obtained at 1
onth, 6 months, and 1 year. Medication use was recorded
n the follow-up forms. In wave 3, clopidogrel was reported
nder cardiac medication-other, whereas in wave 4, patients
ere specifically queried for clopidogrel use. In waves 3 and
, 89.4% and 99.6%, respectively, of enrolled patients
onsented to follow-up. One-year follow-up data was avail-
ble in 93% of wave 3 patients and 96% of wave 4 patients
hat consented to follow-up. Medical records were reviewed
henever possible for patients requiring repeat hospitaliza-
Abbreviations
and Acronyms
BMS  bare metal stent(s)
DES  drug-eluting stent(s)
HR  hazard ratio
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary interventionion. In addition to patient telephone interviews, referring chysicians and institutions were contacted whenever neces-
ary for additional information.
During follow-up, coronary angiography was obtained as
linically indicated by symptoms or documentation of myo-
ardial ischemia. Planned staged PCI was not considered a
epeat PCI. No angiographic reevaluation was performed
nless clinically driven. Lesion-specific data was collected
or repeat PCI if available to determine target vessel
evascularization. In wave 3, 183 patients reported a need
or a repeat PCI, and repeat lesion data was available in 172
atients. In wave 4, 124 underwent a repeat PCI, and repeat
esion forms were available for 111 patients.
efinitions. Death is defined as all-cause mortality. The
nd point of major adverse cardiac events (MACE) includes
eath, MI, and any repeat revascularization, and repeat PCI
ncludes both target and nontarget vessel interventions.
arget vessel revascularization was defined as a repeat
evascularization procedure involving the initially treated
rtery. Specific data on subacute (0 to 30 days) and late (31
ays to 1 year) stent thrombosis was collected in wave 4
n  1,460 DES patients) but not in wave 3. Only definite
tent thrombosis, defined as angiographically confirmed
ases, is reported in this study.
tatistical analysis. Patient characteristics pertaining to
he index PCI, including demographics, medical history,
ardiac presentation, periprocedural medications, proce-
ural characteristics, and in-hospital outcomes were com-
ared between stent types by Student t tests or Wilcoxon
onparametric tests for continuous variables and by chi-
quare test or Fisher exact test for categoric variables.
imilar methods were used for lesion-level analyses. One-
ear event rates were calculated using the Kaplan-Meier
pproach, and unadjusted comparisons of survival curves
ere performed using the log-rank test. Adjusted survival
urves for the composite outcomes death/MI and need for
epeat revascularization were plotted and compared using
nverse probability weights (23). Cox proportional hazards
odeling was used to estimate 1-year hazard ratios (HRs)
or adverse clinical events in relation to stent type and 1-year
eath/MI and target lesion revascularization by PCI in
elation to both lesion morphology and stent type. Covariate
djustment was performed such that clinical, demographic,
nd procedural variables were entered individually into
utcome-specific models that included an indicator variable
or stent type. Confounding variables were assessed in a
orward stepwise manner to determine the final adjusted
odel. The screened variables with a p value of 0.20 were
ncluded in the forward selection process, and those where
he p value was 0.10 remained in the model. All models
ere age adjusted regardless of the p value. The variables
emaining in the final models for adverse events by stent
ype are listed in the Online Appendix. Covariate adjust-
ent for outcomes based on lesion and stent type were done
n a similar fashion. Patients who did not experience the
utcome of interest were censored at the last known date of
ontact or at 1 year if contact extended beyond 1 year.
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November 20, 2007:2029–36 Drug-Eluting Stent Outcomes in North Americaroportional hazards assumptions were evaluated and met.
nteractions between stent type and preselected variables
those thought to be biologically plausible) were formally
valuated. For all analyses, a 2-sided p value of 0.05 was
onsidered to be statistically significant.
esults
aseline and procedural characteristics. Baseline charac-
eristics comparing BMS- and DES-treated patients are
resented in Table 1. Mean age (64.4 vs. 63.7 years) and
emale gender (35.8% vs. 33.3%) were similar between BMS
nd DES patients. The BMS-treated patients were less
ikely to have diabetes (29.1% vs. 34.3%) and other cardio-
ascular risk factors, prior percutaneous coronary revascu-
arization procedures, and comorbidities. The extent of
oronary artery disease did not differ, but the procedural
aseline Characteristics of Patients Treated With atent in the BMS Era Compared With Those Treatedith a DES When Both BMS nd DES Wervailable
Table 1
Baseline Characteristics of Patients Treated With a
Stent in the BMS Era Compared With Those Treated
With a DES When Both BMS and DES Were
Available
Variable
BMS
(n  1,763)
DES
(n  1,460) p Value
Mean age, yrs 64.4 63.7 0.07
Female, % 35.8 33.3 0.14
Mean body mass index, kg/m2 29.3 29.4 0.96
Diabetes, % 29.1 34.3 0.002
Insulin, % 8.9 11.4 0.02
Hypertension, % 74.1 79.1 0.001
Hypercholesterolemia, % 69.8 77.5 0.001
Current smoking, % 24.1 21.4 0.05
Prior myocardial infarction, % 26.2 26.4 0.91
Prior angioplasty, % 27.3 32.4 0.002
Prior coronary bypass, % 17.4 19.2 0.18
Comorbidities, %
Cerebrovascular 6.7 8.7 0.03
Renal insufficiency 7.1 9.1 0.03
Peripheral arterial disease 9.3 9.3 0.99
Ejection fraction, mean % 51.5 52.3 0.09
Vessel disease, %
0 0.3 0.2 0.10
1 37.6 33.8
2 32.0 32.5
3 30.1 33.5
Stenosis 50%, mean 3.1 3.2 0.12
Reason for revascularization, % 0.001
Acute myocardial infarction 29.8 23.8
Unstable angina 39.9 35.9
Stable angina 19.7 25.0
Other 10.6 15.3
Cardiogenic shock, % 2.1 0.5 0.001
Pre- or periprocedural
medications, %
39.9 35.9
Thienopyridines 69.3 87.4 0.001
Glycoprotein IIb/IIIa inhibitor 55.5 33.6 0.001
Heparin 94.8 69.5 0.001
Low-molecular-weight heparin 3.9 5.0 0.11AMS  bare-metal stent; DES  drug-eluting stent.ndication was more often an acute MI in BMS patients
29.8% vs. 23.8%). Medications used before the procedure
iffered between groups, with the DES group receiving
ore thienopyridines and BMS group more glycoprotein
Ib/IIIa inhibitors.
esion characteristics and procedural outcomes. A total
f 2,551 lesions in the BMS group and 1,995 lesions in the
ES group were attempted (Table 2). Lesion location and
eference vessel diameter were similar between groups. There
ere several differences in the types of lesions treated, with
ore total occlusions, thrombus, and bifurcation lesions in
atients treated with BMS and more calcification and complex
esion types by American College of Cardiology/American
eart Association criteria in DES. Although the prevalence of
hese lesion features differed between the 2 groups, the mag-
itudes of the differences were small. Rates of complications
ere low and angiographic success high in both groups.
All patients in the present analysis received at least 1
tent, but not all attempted lesions per patient were stented.
haracteristics and Outcomes of Attempted Lesionsn the BMS Era Compared With Thos Treated WithDES When Both BMS and DES Wer Av ilable
Table 2
Characteristics and Outcomes of Attempted Lesions
in the BMS Era Compared With Those Treated With
a DES When Both BMS and DES Were Available
Variable
BMS
(n  2,551)
DES
(n  1,995) p Value
Location, % 0.10
Left main 1.3 1.4
Left anterior descending 35.4 38.4
Left circumflex 22.5 23.3
Right coronary artery 34.1 31.3
Bypass graft 6.7 5.6
Mean reference vessel
diameter, mm
3.1 3.0 0.07
Mean lesion length, mm 13.4 15.9 0.001
Complex lesion types, %
Total occlusion 9.2 7.4 0.03
Thrombus 15.4 11.0 0.001
Calcified 22.3 26.5 0.001
Ulcerated 12.7 13.1 0.72
Bifurcation 13.2 10.2 0.002
Ostial 6.9 8.8 0.02
ACC/AHA classification 0.001
A 16.6 10.5
B1 34.5 37.5
B2 30.9 31.6
C 18.0 20.4
Stent use overall, % 90.6 95.2 0.001
Sirolimus-eluting stent, % — 59.8 —
Paclitaxel-eluting stent, % — 31.5 —
Procedural complications, %
Major dissection 1.9 2.1 0.74
Perforation 0.2 0.1 0.41
Embolization 0.6 0.7 0.78
Side branch occlusion 2.1 2.2 0.85
Angiographic success, % 97.5 97.9 0.33
CC/AHA American College of Cardiology/American Heart Association; other abbreviations as in
able 1.higher proportion of attempted lesions among DES
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Drug-Eluting Stent Outcomes in North America November 20, 2007:2029–36atients received a stent than in the BMS group (95% vs.
1%, respectively; p 0.001). In the DES group, sirolimus-
luting stents were used in 59.8% of treated lesions and
aclitaxel-eluting stents in 31.5%. Some lesions in the
atients in whom DES was attempted were finally treated
ith BMS only (4.4%) or a combination of DES and BMS
2.3%). The mean number of stents per patient was slightly
igher in the DES patients compared with those receiving
nly BMS (1.6  0.9 vs. 1.5  0.9; p  0.004).
Failure of stent delivery was evaluated in the DES group.
here were 21 lesions where a DES was unable to be
elivered. For 9 lesions, a BMS was successfully deployed
hen a DES failed. In 12 lesions, neither a DES nor BMS
ould be delivered, but the lesion was treated successfully
ith balloon angioplasty.
n-hospital outcomes. Rates of in-hospital mortality
DES 0.5% vs. BMS 1.1%; p  0.06), MI (DES 2.2% vs.
MS 1.9%; p  0.60), and coronary bypass (DES 0.1% vs.
MS 0.3%; p  0.10) were low and similar in both groups.
t discharge, more patients in the DES group were pre-
cribed aspirin (DES 96.8% vs. BMS 94.0%; p  0.001), or
thienopyridine (DES 99.0% vs. BMS 95.5%; p  0.001).
linical outcomes at 1 year. At 1 year, the observed
umulative incidences of death and MI were similar be-
ween the DES and BMS groups (Tables 3 and 4). Patients
reated with DES had significantly less revascularization
han BMS, including target vessel revascularization by PCI
5.0% vs. 9.2%, respectively; p  0.001), any PCI (9.0% vs.
2.7%, respectively, adjusted HR 0.65, 95% confidence
nterval [CI] 0.52 to 0.82; p  0.001), and coronary bypass
urgery (1.2% vs. 3.1%, respectively, adjusted HR 0.34, 95%
I 0.19 to 0.60; p  0.001). Overall MACE was 15.5% in
he DES patients and 20.9% in BMS (adjusted HR 0.67,
5% CI 0.56 to 0.81), with the reduced risk in DES-treated
atients driven by lower repeat revascularization. The 1-year
reedoms from repeat revascularizations for both BMS and
ES patients are depicted in Figure 1, indicating a sub-
tantial divergence at approximately 4 months after PCI
hat is sustained to 1 year. For 1-year freedom from
eath/MI, no divergence of events was noted between BMS
nd DES patients.
umulative 1-Year Event Rates
Table 3 Cumulative 1-Year Event Rates
Variable
BMS
(n  1,763)
DES
(n  1,460) p Value
Death, % 4.3 3.6 0.32
Myocardial infarction, % 4.7 4.6 0.93
Coronary bypass, % 3.1 1.2 0.001
Repeat angioplasty, % 12.7 9.0 0.001
Target vessel revascularization,* % 9.2 5.0 0.001
MACE, % 20.9 15.5 0.001
This only applies to patients who reported an unplanned percutaneous coronary intervention and
or whom repeat lesion data were available. Index lesions that were not stented with the
ppropriate stent type (i.e., BMS in wave 3 and DES in wave 4) were not included.D
MACEmajor adverse cardiac events: death, myocardial infarction, or repeat revascularization
y angioplasty or coronary bypass; other abbreviations as in Table 1.In subgroup analyses, the overall comparable safety pro-
le of DES versus BMS and the overall reduced need for
epeat revascularization with DES were consistently ob-
erved. The only differential effect noted (p  0.04) was for
he outcome need for repeat revascularization in which the
djusted HR comparing DES to BMS was statistically
ower (but in the same direction) in single-vessel disease
atients (adjusted HR 0.35, 95% CI 0.22 to 0.57) than in
ultivessel disease patients (adjusted HR 0.66, 95% CI 0.51
o 0.85).
One-year event rates according to the complexity of
ttempted lesions are shown in Table 5. The incidence of
eath/MI is greater among patients with one or more
omplex lesion characteristic than in those with none, and
o differences (p  0.05) were noted between BMS and
ES patient subsets. Rates for repeat target vessel revascu-
arization by PCI trended or were significantly lower in
atients receiving DES compared with BMS regardless of
he presence or absence of a specified complex lesion. After
djustment (Fig. 2), these relationships remained, with a
ower risk of repeat target vessel revascularization by PCI in
ES patients irrespective of the presence (HR 0.57, 95% CI
.39 to 0.83) or absence (HR 0.44, 95% CI 0.28 to 0.71) of
ny complex lesion type and no appreciable difference in
eath/MI according to lesion or stent type.
Information regarding stent thrombosis was obtained for
atients enrolled in wave 4 but was not available for previous
aves. Therefore, findings are limited to the DES group
nly. The overall rate of definite stent thrombosis in
ssociation Between Stent TypeDES vs. BMS) and 1-Year Adverse Outcomes
Table 4 Association Between Stent Type(DES vs. BMS) and 1-Year Adverse Outcomes
Adverse Outcome HR 95% CI p Value
Death
Unadjusted 0.83 0.57–1.20 0.32
Adjusted 0.97 0.66–1.43 0.87
Myocardial infarction
Unadjusted 0.99 0.71–1.37 0.93
Adjusted 1.02 0.73–1.43 0.90
Coronary artery bypass graft
Unadjusted 0.39 0.22–0.68 0.001
Adjusted 0.34 0.19–0.60 0.001
Death/myocardial infarction
Unadjusted 0.88 0.68–1.13 0.31
Adjusted 0.88 0.68–1.15 0.34
Repeat angioplasty
Unadjusted 0.69 0.55–0.87 0.001
Adjusted 0.65 0.52–0.82 0.001
Repeat revascularization
Unadjusted 0.64 0.52–0.79 0.001
Adjusted 0.38 0.25–0.60 0.001
MACE
Unadjusted 0.72 0.60–0.85 0.001
Adjusted 0.67 0.56–0.81 0.001
ee the Online Appendix for factors included in adjusted models.
CI  confidence interval; HR  hazard ratio; other abbreviations as in Tables 1 and 3.ES-treated patients was 1.0% (n  14), with 11 events
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November 20, 2007:2029–36 Drug-Eluting Stent Outcomes in North Americaccurring before day 31, and 3 between day 31 and 1 year.
ll 3 late thrombosis events presented as acute MI and were
onfatal. One occurred at day 37 in a single Taxus stent
Boston Scientific, Natick, Massachusetts) in the left ante-
ior descending artery. The second was at day 91 in a
ifurcation lesion involving the left anterior descending
reated with 2 Cypher stents (Cordis, Miami Lakes, Flor-
da) using the crush technique. The third was at day 344 in
Taxus stents in the left circumflex artery, 2 weeks after
iscontinuing aspirin and clopidogrel in preparation for a
urgical procedure.
For patients that consented to follow-up after discharge,
ho did not die, and had a 1-year follow-up form, 15.6% in
ave 3 reported using clopidogrel and 61.3% in wave 4 at 1
ear (p  0.001). Aspirin use was 85.8% in wave 3 and
0.7% in wave 4 (p  0.001). Baseline characteristics and
elected outcomes were assessed according to clopidogrel
se at 1 year in wave 4 patients. Compared with nonclo-
idogrel users, clopidogrel users were more likely to have
rior PCI (37.3% vs. 25.2%; p .0001), previous treat-
ent with a stent, prior MI (28.8% vs. 23.4%; p  0.03),
Figure 1 Adjusted Kaplan-Meier Event Curves at 1 Year
Adjusted Kaplan-Meier event curves at 1 year for (A) freedom from death/myo-
cardial infarction by stent type and (B) freedom from need for repeat revascu-
larization rates by stent type.nd multivessel disease. At 1 year, MIs were reported in o.1% of non-clopidogrel users and 3.9% of clopidogrel
sers (p  0.50), and the rate of repeat PCI was higher
n the clopidogrel users (3.9% vs. 11.6%, respectively; p 
.001).
iscussion
espite the expanded use of DES in patient and lesion
ubsets that were more complex than in randomized con-
rolled trials, we found that patients treated with DES had
substantial reduction in clinically driven target vessel
evascularization compared with BMS-treated patients. The
verall risk of repeat revascularization by PCI or coronary
ypass after adjustment was 43% lower in DES patients,
onfirming the important contribution of target vessel
evascularization, presumably from in-stent restenosis, to
his end point. Importantly, these favorable treatment ef-
ects were achieved without excess hazard of death or MI;
oreover, we observed a low rate of late stent thrombosis in
ES patients.
ne-Year Event Rates* for Complexesion Types in P ients by Stent Type
Table 5 One-Year Event Rates* for ComplexLesion Types in Patients by Stent Type
BMS DES
p Valuen % n %
Death or MI
Bifurcation  261 9.3 189 6.4 0.32
Bifurcation  1,502 8.6 1,271 7.8 0.44
Ostial  163 12.1 168 11.4 0.92
Ostial  1,600 8.3 1,292 7.1 0.22
Thrombus  329 13.1 189 10.9 0.45
Thrombus  1,434 7.7 1,262 7.1 0.59
Calcification  424 9.7 407 9.2 0.89
Calcification  1,339 8.3 1,053 6.9 0.20
Ulceration  282 9.8 225 9.5 0.91
Ulceration  1,481 8.5 1,235 7.2 0.26
TO  212 12.1 143 12.9 0.93
TO  1,551 8.2 1,371 7.0 0.27
Any present 1,053 10.3 852 8.6 0.24
None present 710 6.3 608 6.2 0.93
TVR via PCI†
Bifurcation  225 8.6 182 7.2 0.67
Bifurcation  1,229 9.3 1,230 4.6 0.001
Ostial  137 10.5 163 5.6 0.12
Ostial  1,317 9.1 1,249 4.9 0.001
Thrombus  258 7.6 190 3.4 0.058
Thrombus  1,196 9.6 1,222 5.2 0.001
Calcification  362 9.3 399 6.2 0.11
Calcification  1,092 9.2 1,013 4.5 0.001
Ulceration  225 5.9 220 5.1 0.70
Ulceration  1,229 9.8 1,192 4.9 0.001
TO  168 8.6 136 2.3 0.023
TO  1,286 9.3 1,276 5.2 0.001
Any 871 8.8 828 5.2 0.004
None 583 9.9 584 4.6 0.001
Rates calculated using Kaplan-Meier methodology. †Target vessel revascularization (TVR) by PCI
excludes patients without repeat lesion forms, as described in Table 3).
MI  myocardial infarction; PCI  percutaneous coronary intervention; TO  total occlusion;
ther abbreviations as in Tables 1 and 3.
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Drug-Eluting Stent Outcomes in North America November 20, 2007:2029–36In this investigation, we compared outcomes for DES
atients with similar types of patients receiving BMS when
hey were used broadly before commercialization of DES.
lthough separated in time by a few years, no other
echnologic advances other than DES occurred between
ecruitment of the BMS and DES patients. We believed
hat the patients who received BMS in this investigation
ould have likely received a DES had they been available. A
arge proportion of both BMS and DES patients had
igh-risk clinical features, including diabetes mellitus and
cute coronary syndromes, and lesion characteristics, includ-
ng ostial, bifurcation, calcified, and total occlusion lesions.
lthough there were statistical differences in baseline and
esion characteristics that may limit comparisons, some
avored BMS and others DES, and adjustment had no
eaningful influence on any of the outcomes. Finally, when
aseline differences were observed, the absolute magnitude
f these differences was small.
The present prospective observational study, carried out
Figure 2 Adjusted HRs and 95% CIs for 1 Year
Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for 1 year (A) dea
revascularization by percutaneous coronary intervention, according to lesion and st multiple centers in North America and inclusive of both airolimus- and paclitaxel-eluting stents, demonstrated a
linically driven target vessel revascularization rate of
.0% in DES- and 9.2% in BMS-treated patients. The
MS patients had lower rates of target vessel revascular-
zation than observed in earlier randomized trials of BMS
ersus DES that included protocol-driven angiographic
ollow-up as part of the trial design (2,3,24). In the
IRIUS (Sirolimus-Eluting Stent in Coronary Lesions)
rial, the BMS arm had a high target lesion revascularization
ate of 20% at 12 months compared with 4.9% for the SES
rm (24). Similarly, in the TAXUS (Paclitaxel-Eluting
tents in the Treatment of Longer Lesions) IV trial, the
MS arm had target vessel revascularization rate of 17.1%
ompared to 7.1% for the PES arm (2). Whether BMS stent
esign, need for angiographic follow-up, or both contrib-
ted to those higher rates of target lesion revascularization is
nclear. Patients in the randomized TAXUS V trial, which
ncluded complex lesions (type B2/C lesions) in 78% of
atients, had target vessel revascularization rates of 12.1%
ocardial infarction and (B) target vessel
pes. BMS  bare-metal stent; DES  drug-eluting stent.th/my
tent tynd 17.3% for the PES and BMS groups respectively (3).
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November 20, 2007:2029–36 Drug-Eluting Stent Outcomes in North Americaccounting for increased rates in both groups in the setting
f angiographic follow-up in this trial, the absolute magni-
ude of reduction we observed for unselected patients in
outine practice were similar.
Compared with other registries, such as the RESEARCH
Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiol-
gy Hospital) registry, we observed higher absolute event
ates but similar trends in outcomes (25). Both registries
howed that compared with BMS patients, DES patients
ad lower rates of target vessel revascularization and
ACE and similar rates of death and MI.
In the SCAAR (Swedish Coronary Angioplasty Regis-
ry), at up to 3 years of follow-up, the adjusted rate of any
epeat PCI or revascularization was lower in DES patients
ut the absolute rates were similar (26). A repeat revascu-
arization procedure was performed in 15.2% of patients
nitially treated with DES and in 16.5% with BMS. Clin-
cally driven restenosis, however, was 60% lower among
ES patients compared with BMS patients, with an abso-
ute reduction of approximately 3%. The composite risk of
eath and MI was similar in patients with DES and BMS,
ut a higher risk of mortality was suggested after 6 months
n the DES patients (26). Whether a longer duration of dual
ntiplatelet therapy or the shorter follow-up period in the
ynamic Registry is responsible for the different findings is
nclear. Dynamic Registry patients overall, however, were
lder and more often had diabetes mellitus and acute
oronary syndromes than in the RESEARCH registry and
ad more diabetes mellitus, hypertension, and prior PCI
nd coronary bypass than the SCAAR, reflecting different
isk profiles in the studies. These differences may reflect
ariations between multicenter versus single-center practice
atterns within and outside the U.S. The characteristics of
atients in the Dynamic Registry and the DEScover regis-
ries, both carried out primarily in U.S. centers, are similar
s are the 1-year event rates (21). Unlike the DEScover
egistry, the present report contains far more BMS patients
ith baseline features more similar to the comparative DES
ohort.
In terms of safety, we observed similar low in-hospital
omplications in BMS and DES treated patients. As in
andomized trials and the RESEARCH registry, no signif-
cant difference was observed in the observed rates of death
nd MI at 1 year (1,2,25). Over 1 year, we observed stent
hrombosis in 1.0% of DES patients, with 0.2% occurring
fter 30 days. In the RESEARCH registry, angiographically
ocumented stent thrombosis occurred in 0.4% of SES
ithin 30 days and no additional cases were observed out to
year. Using a similar definition as the Dynamic Registry,
ES patients in DEScover had an adjudicated stent throm-
osis rate of 0.6% at 1 year. In a recent meta-analysis of 14
andomized trials comparing DES and BMS, the rate of
tent thrombosis for DES after 30 days was 0.5% (12).
lthough stent thrombosis may be underestimated in
egistries, owing to less rigorous follow-up than some
andomized clinical trials, the low overall rate in the lynamic Registry is reassuring. Longer follow-up of the
egistry cohort is needed to address the issue of stent
hrombosis occurring after 1 year (i.e., very late stent
hrombosis). Although very late stent thrombosis seems
o occur more frequently in DES- than in BMS-treated
atients, no excess in cardiac death or MI has been
emonstrated (12,13,15,27).
This study adds to our knowledge of how DES performs
n complex lesion subsets. Rates of death and reinfarction
ere lower, but not statistically different, in patients that
ad 1 or more complex lesions treated with DES, including
ifurcation, ostial, thrombotic, calcified, and total occlusion
esions. As expected, however, event rates were higher in
oth DES and BMS patients with 1 or more complex lesion
ype compared with those with no complex lesion type
ttempted. After adjustment for baseline characteristics, no
ppreciable differences were detected in the combined end
oint of death/MI by stent type according to the presence or
bsence of a complex lesion. Additionally, only 1 of the 3
ate stent thrombosis events occurred in a complex lesion
ype. In terms of efficacy, target vessel revascularization was
ower in DES patients compared with BMS patients inde-
endent of lesion complexity. These findings are reassuring
nd support the use of DES in lesions where the device is
onsidered “untested,” including ostial, total occlusion, and
ifurcation lesions.
tudy limitations. Several limitations of the present study
equire comment. Stent selection was not randomized, and
hysician bias in choosing stent type cannot be assessed. We
herefore compared DES patients to those treated with
MS before availability of DES. The DES patients, how-
ver, may be more “selected” than the BMS patients.
nmeasured confounding variables may also exist. Routine
ngiographic follow-up was not a component of the study
esign. As such, we were unable to determine rates of
n-stent restenosis or target lesion revascularization. Evalu-
tion of target vessel revascularization may underestimate
he relative benefit of DES for preventing in-stent restenosis
ue to nonlesion disease progression; however, we did
bserve a significant reduction in this end point with DES.
here were also lesions in both BMS and DES cohorts that
ere treated with balloon angioplasty alone, and some DES
atients also received BMS, but the rates were low, and
hese lesions were excluded from the target vessel revascu-
arization analysis.
We do not have data on the duration of dual antiplatelet
herapy in all patients, and we did not assess whether use
as continuous. In wave 4, however, those on clopidogrel at
-year had more extensive coronary artery disease and prior
CI at baseline and were more likely to undergo repeat PCI
uring follow-up. We observed that cumulative rates of MI
ere similar to non-clopidogrel users but cannot comment
n mortality and clopidogrel use. Lastly, we cannot com-
ent on long-term outcomes, because the current analysis isimited to 1-year follow-up.
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n summary, the present study provides additional informa-
ion regarding the safety and effectiveness of DES. For at
east up to 1 year, use of DES in standard clinical practice was
ot associated with any excess risk of death or MI compared
ith BMS, even in complex lesion subsets. Furthermore, the
urability of the initial percutaneous revascularization was
nhanced with DES.
eprint requests and correspondence: Dr. J. Dawn Abbott,
hode Island Hospital, 814 APC, 593 Eddy Street, Providence,
hode Island 02903. E-mail: jabbott@lifespan.org.
EFERENCES
1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus
standard stents in patients with stenosis in a native coronary artery.
N Engl J Med 2003;349:1315–23.
2. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the
slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the
TAXUS-IV trial. Circulation 2004;109:1942–7.
3. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-
based paclitaxel-eluting stent with a bare metal stent in patients with
complex coronary artery disease: a randomized controlled trial. JAMA
2005;294:1215–23.
4. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents
for treatment of patients with long atherosclerotic lesions in small
coronary arteries: double-blind, randomised controlled trial (E-
SIRIUS). Lancet 2003;362:1093–9.
5. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of
the sirolimus-eluting stent in the treatment of patients with long de
novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll
Cardiol 2006;43:1110–5.
6. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-
blind comparison of sirolimus-eluting stent versus bare-metal stent
implantation in diseased saphenous vein grafts: six-month angio-
graphic, intravascular ultrasound, and clinical follow-up of the RRISC
trial. J Am Coll Cardiol 2006;48:2423–31.
7. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al. Randomized
comparison of sirolimus-eluting stent versus standard stent for percu-
taneous coronary revascularization in diabetic patients: the diabetes
and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:
2175–83.
8. Holmes DR Jr., Teirstein P, Satler L, et al. Sirolimus-eluting stents vs
vascular brachytherapy for in-stent restenosis within bare-metal stents:
the SISR randomized trial. JAMA 2006;295:1264–73.
9. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus
uncoated stents in acute myocardial infarction. N Engl J Med
2006;355:1093–104.
0. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus
uncoated stents in primary percutaneous coronary intervention.
N Engl J Med 2006;355:1105–13.
1. Suttorp MJ, Laarman GJ, Rahel BM, et al. Primary Stenting of
Totally Occluded Native Coronary Arteries II (PRISON II): a
randomized comparison of bare metal stent implantation with
sirolimus-eluting stent implantation for the treatment of total coronary
occlusions. Circulation 2006;114:921–8. p2. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt
DL. Late thrombosis of drug-eluting stents: a meta-analysis of
randomized clinical trials. Am J Med 2006;119:1056–61.
3. Nordmann AJ, Briel M, Bucher HC, Mortality in randomized
controlled trials comparing drug-eluting vs. bare metal stents in
coronary artery disease: a meta-analysis. Eur Heart J 2006;27:2784–
814.
4. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A
pooled analysis of data comparing sirolimus-eluting stents with bare-
metal stents. N Engl J Med 2007;356:989–97.
5. Stone GW, Moses JW, Ellis SE, et al. Safety and efficacy of sirolimus-
and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998–
1008.
6. Mauri L, Hsieh W, Massaro JM, Ho K, D’Agostino R, Cutlip DE.
Stent thrombosis in randomized clinical trials of drug-eluting stents.
N Engl J Med 2007;365:1020–9.
7. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing
sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;
356:1030–9.
8. Pfisterer ME, Brunner-La Rocca HP, Buser PT, et al. Late clinical
events after clopidogrel discontinuation may limit the benefit of
drug-eluting stents: an observational study of drug-eluting versus
bare-metal stents. J Am Coll Cardiol 2006;48:2584–91.
9. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and
outcome of thrombosis after successful implantation of drug-eluting
stents. JAMA 2005;293:2126–30.
0. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and
long-term outcomes of angiographically proven stent thrombosis with
sirolimus- and paclitaxel-eluting stents. Circulation 2006;113:
1108–13.
1. Williams DO, Abbott JD, Kip KE, DEScover Investigators. Out-
comes of 6906 patients undergoing percutaneous coronary intervention
in the era of drug-eluting stents: report of the DEScover registry.
Circulation 2006;114:2154–62.
2. Rao SV, Shaw RE, Brindis RG, et al. Patterns and outcomes of
drug-eluting coronary stent use in clinical practice. Am Heart J 2006;152:
321–6.
3. Cole SR, Hernan MA. Adjusted survival curves with inverse propor-
tional weights. Computer methods and programs in biomedicine
2004;75:45–9.
4. Holmes DR Jr., Leon MB, Moses JW, et al. Analysis of 1-year clinical
outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting
stent versus a standard stent in patients at high risk for coronary
restenosis. Circulation 2004;109:634–40.
5. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted
utilization of sirolimus-eluting stents compared with conventional bare
stent implantation in the “real world”: the Rapamycin-Eluting Stent
Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry.
Circulation 2004;109:190–5.
6. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes
with drug-eluting stents versus bare-metal stents in Sweden. N Engl
J Med 2007;356:1009–19.
7. Ong AT, van Domburg RT, Aoki J, Sonnenschein K, Lemos PA,
Serruys PW. Sirolimus-eluting stents remain superior to bare-metal
stents at two years: medium-term results from the Rapamycin-Eluting
Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH)
registry. J Am Coll Cardiol 2006;47:1356–60.
APPENDIX
or factors included in the adjusted model,
lease see the online version of this article.
